Pilot Diet Study for Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02986893|
Recruitment Status : Active, not recruiting
First Posted : December 8, 2016
Last Update Posted : December 19, 2017
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis||Behavioral: Dietary Intervention Behavioral: Non-dietary Intervention Arm|
This is a pilot study of a carefully-designed dietary intervention that aims to help overcome obstacles to diet research in MS as well as provide needed preliminary data for future clinical trials. It incorporates elements with suggested benefits for MS including foods high in polyunsaturated fatty acids, polyphenols, and antioxidants, and excludes those that are potentially detrimental such as dairy and saturated fat from meat, refined sugars, and also limits salt content.
The 15 participants randomized to the dietary intervention arm will undergo intensive training with a nutritionist and the PI regarding the mechanics of the diet. Menu suggestions, recipes, and grocery lists will be provided. This will be followed by regular meetings and contact with all study participants by e-mail and phone to maximize dietary adherence. The 15 subjects not in the dietary intervention group will have regular meetings at the center with a focus on wellness in MS in general. Adherence to the diet will be assessed through the use of multiple validated dietary questionnaires as well as through biological specimen analysis. Feedback will be requested to provide valuable advice from participants that can be applied to future clinical trials. Effects on general health and wellness outcomes such as BMI, lipid profile, fasting glucose, hemoglobin a1c, blood pressure, as well as effects on fatigue and cognition will be explored. Fecal specimens for microbiota analysis and blood samples for immunological profiling will be collected and stored for future analysis to help elucidate potential mechanisms for dietary effects.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||May 2018|
|Estimated Study Completion Date :||May 2018|
Experimental: Dietary Intervention Arm
Participants will be assigned to follow a specific dietary intervention for 6 months
Behavioral: Dietary Intervention
Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
Experimental: Non-dietary Intervention Arm
Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
Behavioral: Non-dietary Intervention Arm
Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
Other Name: Monthly MS Center meeting attendance
- Food Frequency Questionnaire [ Time Frame: at 6 months ]Adherence to the dietary intervention will be assessed through the food frequency questionnaire. This full-length (approximately 110 food item) questionnaire was designed to estimate usual and customary intake of a wide array of nutrients and food groups. Calculations are estimated via computerized software programs.
- Carotenoids level [ Time Frame: at 6 months ]Adherence to the dietary intervention assessed through the carotenoid biological marker.
- Pooled fatty acids level [ Time Frame: at 6 months ]Adherence to the dietary intervention assessed through the pooled fatty acids biological marker.
- Urinary sodium level [ Time Frame: at 6 months ]Adherence to the dietary intervention assessed through the urinary sodium biological marker.
- Change in Blood pressure [ Time Frame: Baseline, 3 months, 6 months ]Change in Blood pressure at 3 months and 6 months as compared to baseline
- Change in body mass index [ Time Frame: Baseline, 3 months, 6 months ]Change in body mass index at 3 months and 6 months as compared to baseline
- Change in lipid profile [ Time Frame: Baseline, 6 months ]Change in lipid profile at 6 months as compared to baseline
- Change in fasting glucose level [ Time Frame: Baseline, 6 months ]Change in fasting glucose at 6 months as compared to baseline
- Change in hemoglobin a1c level [ Time Frame: Baseline, 6 months ]Change in hemoglobin a1c at 6 months as compared to baseline
- Change in Multiple Sclerosis Impact Scale-29 (MSIS-29) [ Time Frame: Baseline, 3 months, 6 months ]Change in quality of life questionnaire scores as assessed by the Multiple Sclerosis Impact Scale-29 at 3 months and 6 months as compared to baseline. The MSIS-29 is a new measure of the physical and psychological impact of MS from the patient's perspective. Each item is scored from 1 (not at all) to 5 (extremely), with total scale from 29 to 145.
- Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54) [ Time Frame: Baseline, 3 months, 6 months ]Change in quality of life questionnaire scores as assessed by the Multiple Sclerosis Quality of Life-54 questionnaire at 3 months and 6 months as compared to baseline. The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items into a single instrument. There is no single overall score for the MSQOL-54. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores.
- Change in the Minimum Assessment of Cognitive Function in MS (MACFIMS) [ Time Frame: Baseline, 6 months ]Change at 6 months from baseline. Total range of MACFIMS from 0 (severe impairment to 282 (severe impairment) which is composed of 7 neuropsychological tests: 1) Controlled Oral Word Association Test (COWAT) score 0 (nonverbal) to 22 (normal verbal fluency; 2) Judgment of Line Orientation (JLO) score 0 (no visuospatial skills) to 30 (normal visuospatial skills); 3) California Verbal Learning Test, 2nd ed (CLVT-II) score 0 (severe deficit) to 16 (normal recall); 4) Brief Visuospatial Memory Test—Revised (BVMT-R) score 0 (poor visuospatial memory) to 12 (normal visuospatial memory); 5) Paced Auditory Serial Addition Test (PASAT) score 0 (poor cognitive function) to 60 (normal cognitive function); 6) Delis-Kaplan Executive Function System (DKEFS) score 0 (poor cognitive function) to 32 (higher levels of creative and abstract thought ); and 7) Symbol Digit Modalities Test (SDMT) score 0 (neurological impairment) to 110 (no impairment ).
- Neurological Fatigue Index-MS [ Time Frame: Baseline, 6 months ]Change in fatigue scale score (Neurological Fatigue Index-MS) at 6 months as compared to baseline. The Neurological Fatigue Index is a 9 item questionnaire with each item scored 1 (not appropriate) to 7 (agree). The score is calculated by the average response to the questions (adding up all the answers and dividing by 9). full range from 1 to 9 with higher value indicating more fatigue.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02986893
|United States, New York|
|Icahn School of Medicine at Mount Sinai|
|New York, New York, United States, 10029|
|Principal Investigator:||Ilana Katz Sand, MD||Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai|